None listed
Conditions
Brief summary
Dystonia is a movement disorder characterised by involuntary twisting movements and abnormal postures of the body. Cervical dystonia is the most common focal dystonia of younger adults, producing abnormal neck postures, twisting, shaking and turning movements of the neck, and pain in the neck and shoulders. How dystonia develops is not known. Treatment for cervical dystonia is predominantly with Botulinum toxin. There is compelling evidence for its benefit in reducing symptoms of head posturing and pain, however it requires repeated injections and does not always provide satisfactory outcomes. Botulinum toxin is known to interrupt neuro-muscular interaction, producing focal muscle weakness, however evidence for its use in migraine headache has implicated a direct effect on pain perception. Whether improvement in dystonia with botulinum toxin is related only to motor effects or has a longer term benefit on modulating the dystonia itself is not known. The experience of pain can alter sensory and motor processing related to direct interference with neuroplastic processes or compromised motor performance. Sensory testing has shown decreased sensory function in the affected compared with unaffected hand in people with hand dystonia. This type of sensory testing has not been performed in people with cervical dystonia. It is likely all dystonia arises from abnormal sensorimotor integration processes, though this process is currently incompletely understood. This project aims to measure peripheral sensory perception objectively in patients with cervical dystonia to determine if their sensation is abnormal, if this is a generalised or focal situation, and to determine if this sensation is altered by the administration of botulinum toxin which is effective in reducing the severity of the movements.
Interventions
Sponsors
Eligibility
Inclusion criteria
Two groups: 1. Cervical dystonia Cervical dystonia as diagnosed by a movement disorders neurologist, aged > 18 years, capable of providing informed consent. The first visit will be held at the end of the botulinum toxin injection cycle, 12 weeks since last injection. 2. control subjects without known neurological disease or chronic pain syndrome
Exclusion criteria
1.Complex dystonia phenotype or familial dystonia 2.Presence of neuropathy (including risk factors as detailed below) a.Diabetes b.Carpal tunnel syndrome c.Major cardiac/respiratory/renal impairment d.Deranged thyroid function e.Significant B12 deficiency f.Autoimmune disease g. Past history of multiple myeloma, chemotherapy h.Cervical spine pathology/radiculopathy i.Co-existing neurological disease or other movement disorder j.Pregnancy k. Drug and alcohol abuse l.HepB/HepC/HIV 3.Inability to speak English to sufficient degree to provide appropriate consent 4.Clinically diagnosed dementia 5.Clinically significant generalised pain disorders including a.Migraine b.Back pain c.Fibromyalgia d.Bruxism/TMJ dysfunction e.CRPS